Chemoinformaics analysis of (-)-ENT-KAURAN-16-BETA-OL
| Molecular Weight | 290.491 | nRot | 0 |
| Heavy Atom Molecular Weight | 256.219 | nRig | 19 |
| Exact Molecular Weight | 290.261 | nRing | 4 |
| Solubility: LogS | -5.838 | nHRing | 0 |
| Solubility: LogP | 5.567 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 4 |
| Atoms Count | 55 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 21 | No. of Aromatic Carbocycles | 0 |
| nHetero | 1 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 4 |
| No. of Hydrogen atom | 34 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 4 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 1 | No. of Arom Bond | 0 |
| nHA | 1 | APOL | 56.873 |
| nHD | 1 | BPOL | 34.109 |
| QED | 0.652 |
| Synth | 5.435 |
| Natural Product Likeliness | 3.275 |
| NR-PPAR-gamma | 0.011 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Accepted |
| Pgp-inh | 0.017 |
| Pgp-sub | 0 |
| HIA | 0.007 |
| CACO-2 | -4.874 |
| MDCK | 0.0000119 |
| BBB | 0.529 |
| PPB | 0.964578 |
| VDSS | 1.515 |
| FU | 0.0367224 |
| CYP1A2-inh | 0.035 |
| CYP1A2-sub | 0.366 |
| CYP2c19-inh | 0.098 |
| CYP2c19-sub | 0.928 |
| CYP2c9-inh | 0.175 |
| CYP2c9-sub | 0.658 |
| CYP2d6-inh | 0.091 |
| CYP2d6-sub | 0.75 |
| CYP3a4-inh | 0.434 |
| CYP3a4-sub | 0.178 |
| CL | 14.957 |
| T12 | 0.07 |
| hERG | 0.013 |
| Ames | 0.01 |
| ROA | 0.039 |
| SkinSen | 0.078 |
| Carcinogencity | 0.026 |
| EI | 0.63 |
| Respiratory | 0.912 |
| NR-Aromatase | 0.602 |
| Antiviral | No |
| Prediction | 0.65174 |